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(01APR2006-30SEP2012) from the U.S. Veterans Health Administration database. The 
first observed treatment date was designated as the index date. Patients were followed 
until the earliest of death, or end of enrollment or study period. Patients were assigned 
to one of four cohorts based on treatment line (TL) number. Treatment combinations, 
length of therapy and incidence rate of death were calculated. Results: A total of 
11,078 patients were included for study, with the majority treated with one TL (63%), 
22% with two, 8% with three and 7% with four TL. The most frequently prescribed 
treatment was 5FU/LV in all first TL (1 TL: 65.8%; 2 TL: 62.3%; 3 TL: 50.1%; 4 TL: 41.0%). 
Patients with three or four TL were prescribed significantly more OX+biologics for 
the first TL than patients with one or two TL. During the second TL, 5FU/LV and OX 
were most frequently prescribed. More variances were observed in the third and 
fourth TL. Length of therapy for each TL ranged from 86 to 104 days. The incidence 
rate of death was similar between patients with one and two TL (19.66 per 100 patient 
years), and higher for patients with three (26.28) and four TL (22.41). ConClusions: 
5FU/LV was the most frequently prescribed first TL. Incidence of death was higher 
in patients with third or fourth TL. The greater diversity in the third and fourth TL is 
likely due to either the absence of proven therapies or the incidence of KRAS with 
tumors. However, multivariate analysis is needed to further confirm these findings.
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objeCtives: Claims data alone are typically lacking in key clinical informa-
tion capturing disease severity, specificity of diagnosis, patient reported out-
comes, and many other factors. Attempts to estimate treatment effects with 
claims data alone, with missing key control variables, have a greater likelihood 
to produce biased result. This study uses claims and lab test results data from a 
large national health plan, in an attempt to circumvent or mitigate problem of 
biases in treatment effect estimators attributed to missing key clinical varia-
bles. Methods: A linked dataset of claims and laboratory results is used to estimate 
treatment effect on resource utilization for a Hepatitis C (HCV) sample (N= 2031). 
To empirically assess the bias from omitting the clinical information in the 
laboratory results (APRI scores), treatment effects are estimated using claims 
alone. Laboratory results are then attached to the claims through statistical link-
ages of records from clinical records and claims records, simulating the statisti-
cal linkage of medical datasets in situations where direct patient-level linkages 
are not possible. Estimation of treatment effects were calculated through the 
bootstrap method by running negative binomial count regressions 500 times 
in samples with replacement size of 500. Results: The results from the data-
set with the linked laboratory results showed bias reduction of 78.8% and 23.8% 
in HCV-related ambulatory visits and All-cause ambulatory visits, respectively. 
Statistical linkages do not appear to have any impact on the treatment effect esti-
mators in the ER visit outcomes which are confirmed by the lack of correlations in 
APRI scores and outcomes. ConClusions: When confronted with missing key clini-
cal variables, record linkage has the effect of reducing bias in treatment effects. The 
degree of this bias reduction will be a function of the strength of the correlations 
among the missing variable, the treatment variable, and the outcome variable.
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objeCtives: Patients’ self-reported drug exposure (PS) is likely to be subject to 
recall and other biases. However, physicians’ medical records (MR) are unable to 
capture noncompliance or over the counter drugs (OTC). This study compared PS 
to MR for vaccinations, musculoskeletal disorder medications (MSD) and cardiovas-
cular drugs (CVD). Methods: The international Pharmacoepidemiologic General 
Research Extension (PGRx) uses a network of over 300 general practitioners across 
France, continuously recruiting an age/gender stratified sample of patients, with-
out reference to diagnoses or prescriptions. PS were obtained using a structured 
interview and an interview guide containing lists of commonly used drugs. PS and 
MR were compared in the three (vaccinations) or two (MSD and CVD) years drug 
taking history. Results: Agreement between PS and MR were investigated using 
7613 (vaccinations), 4152 (MSD) and 2072 (CVD) patient-physician pairs. For vacci-
nations, prevalence and bias –adjusted kappa (PABAK) values were substantial for 
influenza vaccines (0.74) and high for 23-valent pneumococcal vaccines (0.98) and 
human papillomavirus vaccines (0.92). For MSD, PABAK values ranged from low for 
non-aspirin non-steroidal anti-inflammatory drugs (0.26 to 0.32), to fair for non-
narcotic analgesics (0.21 to 0.50), fair to substantial for muscle relaxants (0.55 to 
0.71) and high for osteoarthritis drugs (0.84 to 0.94). For CVD, overall agreement was 
excellent (kappa = 0.83, 95% CI = 0.81 -85). Disagreement was higher for OTC MSD 
and CVD (odds ratios= 1.21 and 8.62 respectively, 95% confidence intervals= 1.05-1.38 
and 4.36-17.05). ConClusions: In the PGRx database, agreement between PS and 
MR tended to remain stable over long recall periods. However, less agreement was 
reported for OTC drugs than prescription drugs/vaccines. Electronic health care 
databases is a valid source of information for drugs available only by prescription, 
but information from patients should be obtained for drugs available OTC in order 
to avoid systematic errors.
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objeCtives: There are few studies of treatment patterns among elderly, newly 
diagnosed Stage IV breast cancer (BC) patients receiving human epidermal growth 
factor receptor 2- (HER2-) targeted therapy. Methods: Women aged 65+ with 
an incident diagnosis of Stage IV BC (index) and no history of other cancer were 
identified from 2006-2010 linked Surveillance, Epidemiology, and End Results 
(SEER) and Medicare data. Continuous enrollment from 1 year pre-index (baseline) 
through disenrollment, death, or the end of the data (follow-up) was required. 
Patients were required to receive HER2-targeted therapy (trastuzumab or lapa-
tinib) during follow-up. Treatment therapies during follow-up were evaluated, 
as was the distribution of treatment combinations. Initial treatment regimens 
were evaluated based on the treatment(s) received after index. A 42-day gap in 
therapy or the addition of a biologic therapy was used as a marker for a subsequent 
regimen. Results: 173 patients were identified (mean [SD] age: 73.9 [6.7]). The 
majority received trastuzumab (98.8%) during follow-up (mean [SD] duration: 24.3 
[11.3] months), with 9.8% receiving lapatinib. Most received chemotherapy (83.2%), 
approximately half received surgery (55.5%), over 40% received hormonal therapy, 
and one-third received radiation (35.3%). Trastuzumab + chemotherapy was the 
most common initial treatment regimen (43.9%); less common therapies include 
trastuzumab alone (17.3%), and trastuzumab + chemotherapy + hormonal (13.3%). 
Among those with subsequent treatment lines, approximately one-fifth of patients 
received chemotherapy alone and another fifth received trastuzumab plus chemo-
therapy. Among patients receiving chemotherapy, the majority received a taxane-
based chemotherapy with fewer patients receiving antimetabolites, vinca alkaloid 
and platinum-based chemotherapy. Treatment pattern and sequencing were simi-
lar using 30-day or 90-day gap in therapy. The average treatment duration for any 
treatment regimen was just less than a year (44.9-52.5 weeks). ConClusions: 
Among Medicare patients with Stage IV BC receiving a HER2-targeted agent, the 
majority received taxane-based combination chemotherapy, consistent with NCCN 
guidelines.
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objeCtives: To assess medical-resource use for commercially-insured patients 
with low back pain (LBP) in the United States. Methods: We identified patients 
with new LBP episodes using inclusion/exclusion criteria consistent with the Back 
Pain Outcomes using Longitudinal Data (BOLD) registry, using the Marketscan® 
Research Databases (2007-2011). We required four years of continuous enrollment, 
one year prior to index with no evidence of spinal surgery, and six-months prior 
without lumbar spine-related care. We used clustering algorithms to identify LBP-
related health care resource use groups over three years, assessing LBP-related 
use of imaging, provider visits, medications, injections, and surgeries. Results: 
513,980 patients (54% female, mean age: 45.2 years) met criteria. Clustering 
approaches grouped patients as very low (30%, one quarter in first year only), low 
(40%), medium (23%), or high (7%) users. Care patterns among groups were con-
sistent for imaging, provider visits, injections, and medications, with higher-use 
groups having greater intensity of and variability in use among nearly all resource 
use types. Lumbar x-ray use was approximately 30% for all groups (year 1). Lumbar 
MRI rates ranged from 14%-19% (year 1), and 2%-15% (years 2-3), increasing by 
group. Chiropractic and physical therapy visits were prevalent (30%-50%, year 1), 
and remained high in higher-use groups. Highly-prescribed medications included 
long-acting opioids, non-steroidal anti-inflammatory drugs, muscle relaxants, and 
anti-depressants, with consistent three-year patterns among use groups. Opioid 
use was high (25%-41% year 1, 15%-51% years 2-3). Trends in average number of 
opioid days supplied by low-, medium-, and high-use groups increased each year 
(ranges (# days): 32-102 year 1, 49-165 year 2, 51-176 year 3). ConClusions: New 
LBP episodes were associated with substantial rates of imaging, provider visits, 
and medication use in commercially-insured patients, with the highest use in the 
first year following diagnosis, and persisting high use for select patients during 
two additional years.
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objeCtives: Examine treatment combinations and mortality rate of colorectal 
cancer (CRC) patients in the U.S. veteran population. Methods: Adult patients 
with at least one primary CRC diagnosis and CRC treatment (5-fluorouracil 
[5-FU]/LV [leucovorin, levoleucovorin]+/-biologics; Irinotecan [IRI]+/- biologics; 
Oxaliplatin [OX]+/-biologics; IR+OX [IROX]+/-biologics; or biologics only) were selected 
